Skip to content

News

Current Year

CGPA and Biosimilars Canada Statement on Proposed Pharmacare Legislation

The generic and biosimilar medicines industries will need to learn more about the Government of Canada’s approach to implementation, and consult with key stakeholders, to help ensure that a transition to this program would maximize the use of cost-saving generic and biosimilar medicines, while protecting Canada’s drug supply and domestic manufacturing capacity.

Read More...

The pan-Canadian Pharmaceutical Alliance and the Canadian Generic Pharmaceutical Association have successfully negotiated a Renewed Three-Year Generics Initiative

The pan-Canadian Pharmaceutical Alliance (pCPA), consisting of participating federal, provincial, and territorial government public drug plans and the Canadian Generic Pharmaceutical Association (CGPA) have successfully reached an agreement on a renewed three-year pricing initiative for generic medicines that will help public drug plans continue to control their costs.

Read More...